Oragenics Inks US-Based Drug Manufacturing Deal with Sterling Pharma Solutions for Concussion Treatment Candidate ONP-002

Oragenics has partnered with Sterling Pharma Solutions to manufacture ONP-002, a drug candidate for treating concussions, at a U.S.-based facility. The partnership supports Phase IIb clinical trials expected to start in 2026, which aim to assess ONP-002's efficacy in treating mild traumatic brain injury. The agreement enhances domestic manufacturing capacity and could provide a much-needed therapeutic option for the condition, currently lacking FDA-approved treatments.